Year: 2022

VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce third quarter financial results for the three and nine months ended September 30, 2022. SafetyStrong focus on safety with one of the best safety records in the Australasia region since commencement of operations. Proactive and focused management of COVID-19. K92 has continuously operated throughout the COVID-19 pandemic, and has strong preventative and response plans that remain in place.ProductionRecord ore processed during the quarter of 117,938 tonnes, or 1,282 tonnes per day (“tpd”), significantly exceeding the Stage 2 Expansion run-rate and a 35% increase from Q3 2021. Record monthly ore processed achieved in August, averaging 1,373 tpd, 25% above the Stage 2 Expansion...

Q2 FY2023 total revenue of $33.2 million grew by 32.4% compared to $25.1 million in Q2 FY2022 Recurring Revenue (1)grew by 36.5% from $19.4 million in Q2 FY2022 to $26.5 million in Q2 FY2023 Positive Adjusted EBITDA(2) of $1.4 million for Q2 FY2023 compared to an Adjusted EBITDA loss(2) of $0.4 million in Q2 FY2022 Sale of Intertrade Systems Inc. on October 4, 2022 for total all-cash consideration of $65.8 million(3)(US$48.5 million) Non-cash intangible asset impairment charge of $85.0 millionMONTREAL, Nov. 14, 2022 (GLOBE NEWSWIRE) — mdf commerce inc. (the “Corporation”) (TSX:MDF), a SaaS leader in digital commerce technologies, reported Q2 FY2023 financial results for the three-month period ended September 30, 2022 (Q2 FY2023). Financial references are expressed in Canadian dollars unless otherwise indicated. “This quarter...

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Shawcor Ltd. (“Shawcor” or the “Company”) (TSX: SCL) reported today its operational and financial results for the three and nine months ended September 30, 2022. This press release should be read in conjunction with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operation (the “MD&A”) and condensed interim consolidated financial statements for the three and nine months ended September 30, 2022, which are available on the Company’s website and at www.sedar.com. Highlights from the third quarter of 2022 include:On a consolidated basis, revenue was $335 million, income from operations was $23 million and Adjusted EBITDA1 was $40 million, which includes expenses of over $9 million of share-based incentive compensation costs partially offset by...

HOUSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Nauticus Robotics, Inc. (“Nauticus” or the “Company”) (NASDAQ: KITT), a developer of ocean robots, autonomy software, and services to the marine industries, today announced results for its third quarter ended September 30, 2022 and provided a business update. Recent Operational and Financial HighlightsCompleted a business combination with CleanTech Acquisition Corp. (“CLAQ”) on September 9, 2022, generating net proceeds of $58.7 million to fund the operations and the initial buildout of Nauticus’ fleet of tandem ocean robots Entered into an agreement with Shell to deploy a Nauticus Aquanaut and its autonomous behaviors using remote operations and supervised autonomy Announced a multi-million-dollar contract with the U.S. Defense Innovation Unit (“DIU”) for the development of an unmanned...

Announces record revenue of $11.2 million Reaffirms 2022 Revenue Guidance to Exceed $43 million Increases 2023 Revenue Guidance to at least $54 million Announces 2023 Adjusted EBITDA Guidance of 15%LOUISVILLE, Ky., Nov. 14, 2022 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX, CREXW), a leading provider of digital signage solutions, announced its financial results for the three- and nine-months ended September 30, 2022. Rick Mills, Chief Executive Officer, commented, “I am pleased to report that the Company generated record revenue of $11.2 million for the third quarter of 2022, a $6.4 million, or 135%, improvement over the same period in 2021. Importantly, this represents a $3.5 million increase over the pro forma combination of Creative Realities and Reflect Systems...

Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis On track to file New Drug Application for RENAZORB in 2023 Expect clearance for a Phase 1 healthy volunteer study of UNI-494, a novel proprietary drug targeting the SUR2B subunit of the mitochondrial KATP channel, in the UK by year-end LOS ALTOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) —  Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2022, and provided a business update. Management Commentary “The third...

Conference call will be held on November 14th at 10AM ET VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, today reported third quarter 2022 financial results for the period ending September 30, 2022. The financial statements and MD&A are available on SEDAR under the Company’s profile. Third Quarter 2022 Financial HighlightsRevenues were $2.2M, an 83% increase versus 1.2M in 3Q21, and 4% decline versus $2.31M in 2Q22. The growth pause in revenues was due to a temporary product shortage driven by a mechanical malfunction at the Company’s US facility, which delayed production by about six weeks. The demand for the products stayed very high. Management...

Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidate Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer accepted by the FDA Enrollment in the Phase 2 study of HB-200 in combination with pembrolizumab is ongoing; next data update expected in the first half of 2023NEW YORK and VIENNA, Austria, Nov. 14, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today reported business highlights and financial results for the third quarter of 2022. “We’re proud of our steady momentum and the external validation of our arenaviral technology over the...

– Direct cost of production $500 lower at $9,400 per BTC –– 1,515 BTC mined in Q3 2022 and 486 BTC in October 2022 –– Quarter ended with 4.2 EH/s, Up 17% from June 30, 2022 –– Final stages of Canadian expansion projects on track for completion by year end – This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated August 16, 2021 to its short form base shelf prospectus dated August 12, 2021. TORONTO, Ontario and BROSSARD, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ: BITF // TSX: BITF), a global Bitcoin self-mining company, reported its financial results for the third quarter ended September 30, 2022. All financial references are in U.S. dollars. During third quarter 2022, Bitfarms mined 1,515 bitcoin...

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. “This has been a transformative year for us, and we’ve achieved important milestones that help us advance toward our goal of developing first in class genetic medicines with the potential to address a broad range of inner...